In a recent gathering on Thursday, shareholders of SELLAS Life Sciences Group (NASDAQ:SLS), Inc., a pharmaceutical company known for its cancer therapies, voted on key proposals affecting the company’s governance and oversight. At the Annual Meeting held on June 20, 2024, the stockholders re-elected Class II directors and ratified the appointment of the company’s independent auditor.
The re-election of directors David A. Scheinberg and Katherine Bach Kalin was confirmed, with Scheinberg securing 8,633,329 votes in favor and 2,721,754 withheld, while Kalin received 8,808,845 votes for and 2,546,238 withheld. A significant number of broker non-votes were recorded for both directors, tallying at 18,651,925.
Moreover, the appointment of Moss Adams LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024, was ratified with a substantial majority of 27,778,751 votes for, 1,743,924 against, and 484,333 abstentions.
In matters of executive compensation, a non-binding advisory resolution was approved by the stockholders, with 5,992,510 votes for, 4,808,398 against, and 554,175 abstentions. This vote reflects the shareholders’ general approval of the compensation given to the company’s named executive officers.
No other proposals were presented or voted upon during the Annual Meeting. This information is based on a press release statement from the company, as detailed in a Form 8-K filed with the Securities and Exchange Commission on June 21, 2024.
The outcomes of these votes are significant for SELLAS as they continue to navigate the competitive pharmaceutical landscape, focusing on the development of novel cancer therapies. The re-elected directors and the ratified auditor will play crucial roles in steering the company through its strategic and financial decisions in the upcoming years.
In other recent news, SELLAS Life Sciences Group has made significant strides in its clinical trials for acute myeloid leukemia (AML) treatments. The company reported preliminary data from its Phase 2a trial of SLS009, which achieved a 57% overall response rate in the selected 30 mg bi-weekly dose cohort.
This surpasses the targeted 20% rate, demonstrating promising potential for patients with specific genetic mutations in AML. SELLAS has also expanded the trial to include cohorts with ASXL1 mutations and other myelodysplasia-related molecular abnormalities.
Moreover, the Independent Data Monitoring Committee (IDMC) has advised SELLAS to proceed without changes with its Phase 3 REGAL trial of galinpepimut-S (GPS) for patients with AML. The IDMC found no safety concerns and deemed the efficacy and safety data sufficient to continue the study as planned.
SELLAS has completed enrollment for its Phase 3 REGAL study of GPS in AML and shared promising topline data from its Phase 2a study of SLS009. The company is considering initiating discussions with the U.S. Food and Drug Administration (FDA) regarding an accelerated approval pathway for SLS009 in this molecularly defined AML patient population. These are recent developments indicating SELLAS's ongoing commitment to improving treatments for AML.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.